AnaptysBio, Inc.
ANAB
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Profil
AnaptysBio, Inc., biotechnologická společnost v klinickém stádiu, se zabývá vývojem léčebných přípravků pro zánětlivé a imuno-onkologické indikace. Mezi jeho produkty patří Imsidolimab, protilátka, která inhibuje receptor interleukinu- 36 (IL- 36R) pro léčbu různých dermatologických zánětlivých onemocnění; Rosnilimab, program anti-PD- 1 agonistických protilátek určený k posílení PD-1 signalizace prostřednictvím léčby rosnilimabem k potlačení lidských zánětlivých onemocnění poháněných T buňkami; a ANB032, anti-BTLA modulátorová protilátka použitelná na lidská zánětlivá onemocnění spojená s lymfoidní a myeloidní dysregulací imunitních buněk. Společnost se také zaměřuje na vývoj různých programů proti tvorbě protilátek, které jsou v rámci spolupráce s ní vyspělé až do preklinických a klinických milníků. Má smlouvu o spolupráci a licenci se společnostmi GlaxoSmithKline, Inc. a Bristol-Myers Squibb a licenční smlouvy se společností United Kingdom Research and Innovation a společností Millipore Corporation. Společnost byla dříve známá jako Anaptys Biosciences, Inc. a v červenci 2006 změnila svůj název na AnaptysBio, Inc. AnaptysBio, Inc. byla založena v roce 2005 a sídlí v San Diegu v Kalifornii.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
136
Založení
2017-01-26
Podobné společnosti
$ 14.19
+ $ 0.29
$ 19.42
+ $ 0.18
$ 13.67
+ $ 0.42
$ 11.85
+ $ 0.15
$ 23.89
+ $ 0.65
$ 12.41
+ $ 0.10
$ 18.44
+ $ 0.81
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 234.6 | 234.6 | 91.3 | 17.2 | 10.3 | 63.2 | 75.0 | 8.0 | 5.0 | 10.0 | 16.7 | 17.6 | 15.8 | 5.5 | |
| Cost of Revenues | 2.4 | 2.4 | 163.8 | 2.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Gross Profit | 232.2 | 232.2 | -72.6 | 14.8 | 10.3 | 63.2 | 75.0 | 8.0 | 5.0 | 10.0 | 16.7 | 17.6 | 15.8 | 5.5 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 108.2 | 76.3 | 22.3 | 27.8 | 43.1 | 30.0 | 11.0 | 7.2 | 9.0 | 3.3 | |
| Cost of Revenues | -108.0 | 31.4 | 37.8 | 41.2 | 42.6 | 42.2 | 42.0 | 37.0 | 0.6 | 0.6 | |
| Gross Profit | 216.2 | 44.9 | -15.6 | -13.4 | 0.5 | -12.2 | -31.0 | -29.9 | 8.4 | 2.7 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 132.3 | 88.8 | 98.5 | 80.0 | 99.3 | 56.2 | 29.4 | 15.4 | 17.3 | 8.6 | 8.8 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 41.9 | 36.6 | 21.5 | 18.9 | 16.1 | 15.5 | 9.3 | 4.3 | 3.6 | 2.4 | 2.0 | |
| Depreciation & Amortization | 2.4 | 2.4 | 2.4 | 2.4 | 7.6 | 0.5 | 4.5 | 11.0 | 0.3 | 0.2 | 0.2 | 0.3 | 0.3 | 0.6 | |
| Total Operating Expenses | 184.3 | 184.3 | 42.4 | 181.6 | 125.4 | 120.0 | 98.9 | 115.4 | 71.7 | 38.8 | 19.7 | 20.9 | 11.0 | 10.8 | |
| Operating Income | 47.9 | 47.9 | -114.9 | -164.4 | -115.2 | -56.8 | -23.9 | -107.4 | -66.7 | -28.8 | -3.0 | -3.3 | 4.9 | -5.3 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 33.5 | 30.9 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.3 | 10.2 | ||
| Depreciation & Amortization | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | ||
| Total Operating Expenses | 149.3 | 10.2 | 10.6 | 14.1 | 10.2 | 10.6 | 9.3 | 12.3 | 43.8 | 41.1 | ||
| Operating Income | 66.9 | 34.7 | -26.2 | -27.5 | -9.7 | -22.8 | -40.3 | -42.2 | -42.1 | -37.7 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 13.5 | 13.5 | 19.8 | 18.9 | 7.6 | 0.4 | 4.0 | 11.0 | 6.7 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Interest Expense | 79.9 | 79.9 | 50.1 | 18.1 | 21.1 | 1.5 | 0.0 | 1.0 | 1.7 | 1.8 | 0.5 | 0.5 | 1.3 | 0.9 | |
| Other Expense | -61.0 | -61.0 | -30.3 | 0.8 | -13.5 | -1.0 | 3.9 | 9.9 | -0.2 | -1.1 | -0.8 | -1.5 | -0.1 | 0.6 | |
| IBT | -13.1 | -13.1 | -145.2 | -163.6 | -128.7 | -57.8 | -19.9 | -97.5 | -61.8 | -30.1 | -4.3 | -5.3 | 3.5 | -5.5 | |
| Income Tax Expense | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | -0.6 | 0.0 | -0.2 | -0.2 | 1.8 | 0.2 | 0.1 | 1.3 | 0.9 | |
| Net Income | -13.2 | -13.2 | -145.2 | -163.6 | -128.7 | -57.2 | -19.9 | -97.3 | -61.7 | -30.1 | -4.3 | -5.4 | 3.5 | -5.5 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 2.5 | 2.9 | 3.7 | 4.4 | 5.3 | 5.3 | 4.6 | 4.6 | 4.9 | 4.9 | ||
| Interest Expense | 19.7 | 22.5 | 19.6 | 18.1 | 17.4 | 15.4 | 11.0 | 6.3 | 5.0 | 4.4 | ||
| Other Expense | -17.2 | -19.6 | -12.4 | -11.7 | -12.1 | -10.1 | -6.3 | -1.7 | -0.1 | 0.4 | ||
| IBT | 49.7 | 15.1 | -38.6 | -39.3 | -21.8 | -32.9 | -46.7 | -43.9 | -42.2 | -37.3 | ||
| Income Tax Expense | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.9 | 4.4 | ||
| Net Income | 49.6 | 15.1 | -38.6 | -39.3 | -21.8 | -32.9 | -46.7 | -43.9 | -42.2 | -37.3 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-6.08 | $-4.57 | $-2.08 | $-0.73 | $-3.60 | $-2.50 | $-1.52 | $-0.23 | $-0.38 | $0.02 | $-0.09 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-6.08 | $-4.57 | $-2.08 | $-0.73 | $-3.60 | $-2.50 | $-1.52 | $-0.23 | $-0.36 | $0.02 | $-0.09 | |
| Shares Outstanding | 27.8 | 27.8 | 28.4 | 26.9 | 28.2 | 27.4 | 27.3 | 27.1 | 24.7 | 19.8 | 18.2 | 14.2 | 14.2 | 58.5 | |
| Diluted Shares Outstanding | 31.3 | 31.3 | 28.4 | 26.9 | 28.2 | 27.4 | 27.3 | 27.1 | 24.7 | 19.8 | 18.2 | 15.0 | 15.0 | 59.7 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-1.59 | $-1.41 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-1.59 | $-1.41 | ||
| Shares Outstanding | 27.8 | 29.1 | 28.8 | 30.6 | 30.4 | 28.8 | 27.4 | 26.8 | 26.6 | 26.5 | ||
| Diluted Shares Outstanding | 31.3 | 29.0 | 28.8 | 30.6 | 30.4 | 28.9 | 27.4 | 26.8 | 26.6 | 26.5 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 71.8 | 123.1 | 36.0 | 71.3 | 495.7 | 250.5 | 171.0 | 113.6 | 81.2 | 51.2 | 51.7 | 22.2 | 2.8 | |
| Short Term Investments | 279.0 | 262.3 | 354.9 | 369.9 | 52.4 | 143.2 | 203.2 | 313.5 | 167.2 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Cash & ST Investments | 350.8 | 385.4 | 390.9 | 441.2 | 548.1 | 393.7 | 374.2 | 427.1 | 248.4 | 51.2 | 51.7 | 22.2 | 2.8 | |
| Accounts Receivable | 9.0 | 40.8 | 6.9 | 1.4 | 0.9 | 0.0 | 0.0 | 0.2 | 1.6 | 5.3 | 1.2 | 1.5 | 0.0 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 7.5 | 5.7 | 9.1 | 4.5 | 4.9 | 2.9 | 3.5 | 7.0 | 2.7 | 1.6 | 0.6 | 0.8 | 0.2 | |
| Total Current Assets | 367.4 | 431.9 | 406.8 | 447.2 | 553.9 | 396.6 | 377.7 | 434.2 | 252.7 | 58.2 | 53.5 | 24.4 | 3.1 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 109.8 | 44.3 | 98.6 | 123.1 | 191.6 | 71.8 | 53.7 | 36.0 | 26.3 | 35.2 | |
| Short Term Investments | 139.1 | 221.4 | 241.3 | 262.3 | 238.5 | 279.0 | 301.0 | 354.9 | 386.8 | 394.3 | |
| Total Cash & ST Investments | 249.0 | 265.7 | 339.9 | 385.4 | 430.1 | 350.8 | 354.7 | 390.9 | 413.0 | 429.5 | |
| Accounts Receivable | 75.7 | 21.4 | 17.9 | 40.8 | 12.2 | 9.0 | 7.1 | 6.9 | 3.3 | 3.2 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 6.0 | 4.8 | 5.3 | 5.7 | 6.4 | 7.5 | 10.7 | 9.1 | 11.7 | 5.9 | |
| Total Current Assets | 330.7 | 291.9 | 363.1 | 431.9 | 448.7 | 367.4 | 372.4 | 406.8 | 428.0 | 438.5 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 17.1 | 16.2 | 18.3 | 20.0 | 21.8 | 1.8 | 1.6 | 1.4 | 0.7 | 0.5 | 0.6 | 0.6 | 0.8 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 42.6 | 35.5 | 27.0 | 142.9 | 67.1 | 17.5 | 54.3 | 73.1 | 75.9 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Long-Term Assets | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.7 | 1.5 | 0.2 | 0.1 | 3.5 | 2.3 | 0.1 | 0.1 | |
| Total Long-Term Assets | 60.0 | 52.0 | 45.6 | 163.2 | 89.2 | 20.0 | 57.5 | 74.8 | 76.7 | 4.0 | 2.8 | 0.7 | 0.9 | |
| Total Assets | 427.4 | 483.8 | 452.4 | 610.4 | 643.1 | 416.6 | 435.2 | 509.0 | 329.4 | 62.2 | 56.3 | 25.1 | 3.9 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 14.5 | 15.1 | 15.7 | 16.2 | 16.6 | 17.1 | 17.7 | 18.3 | 18.9 | 19.1 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 7.7 | 28.0 | 43.0 | 35.5 | 27.9 | 42.6 | 15.5 | 27.0 | 40.2 | 59.2 | |
| Other Long-Term Assets | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| Total Long-Term Assets | 22.4 | 43.3 | 58.9 | 52.0 | 44.7 | 60.0 | 33.4 | 45.6 | 59.3 | 78.6 | |
| Total Assets | 353.1 | 335.3 | 422.1 | 483.8 | 493.4 | 427.4 | 405.8 | 452.4 | 487.3 | 517.1 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 4.9 | 4.0 | 4.7 | 2.8 | 1.7 | 4.2 | 16.2 | 5.4 | 2.3 | 2.3 | 1.5 | 0.4 | 0.2 | |
| Short-Term Debt | 1.9 | 1.9 | 3.6 | 1.6 | 1.5 | 0.3 | 2.2 | 7.6 | 6.9 | 0.0 | 0.0 | 0.1 | 0.9 | |
| Other Current Liabilities | 33.7 | 39.5 | 29.2 | 21.6 | 12.9 | 15.3 | 0.9 | 0.1 | 0.0 | 0.0 | 2.9 | 1.1 | 0.7 | |
| Current Liabilities | 40.4 | 45.4 | 37.4 | 26.1 | 16.1 | 19.8 | 29.5 | 21.8 | 14.1 | 5.7 | 7.4 | 11.7 | 3.2 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 2.9 | 3.3 | 6.1 | 4.0 | 3.6 | 4.9 | 4.6 | 4.7 | 6.5 | 4.8 | |
| Short-Term Debt | 2.0 | 2.0 | 2.0 | 1.9 | 1.9 | 1.9 | 1.8 | 3.6 | 3.5 | 3.4 | |
| Other Current Liabilities | 33.2 | 30.2 | 32.4 | 39.5 | 38.4 | 33.7 | 25.9 | 29.2 | 29.2 | 33.5 | |
| Current Liabilities | 38.1 | 35.5 | 44.0 | 45.4 | 43.9 | 40.4 | 32.3 | 37.4 | 39.2 | 41.6 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 362.0 | 367.5 | 16.0 | 17.8 | 19.5 | 0.0 | 0.0 | 0.6 | 7.6 | 13.8 | 4.9 | 4.8 | 0.0 | |
| Capital Leases | 15.1 | 16.0 | 17.8 | 19.5 | 21.0 | 0.3 | 0.9 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 417.5 | 413.0 | 364.3 | 348.3 | 286.6 | 19.8 | 30.2 | 22.6 | 21.8 | 22.9 | 13.9 | 19.1 | 3.8 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 344.4 | 13.1 | 13.6 | 14.1 | 14.6 | 15.1 | 325.8 | 16.0 | 16.5 | 16.9 | |
| Capital Leases | 0.0 | 15.1 | 15.6 | 16.0 | 16.5 | 16.9 | 15.6 | 17.8 | 18.2 | 18.7 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 382.5 | 380.0 | 388.0 | 413.0 | 409.1 | 417.5 | 358.1 | 364.3 | 366.9 | 368.7 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | -704.7 | -759.3 | -614.1 | -450.5 | -321.8 | -264.0 | -244.0 | -146.7 | -85.0 | -54.9 | -50.7 | -45.3 | -48.8 | |
| Comprehensive Income | -0.4 | 0.3 | -0.8 | -5.2 | -0.4 | 0.0 | 0.3 | -0.2 | -0.4 | -3.8 | -3.6 | -3.4 | -3.1 | |
| Total Common Equity | 9.9 | 70.9 | 88.1 | 262.1 | 356.4 | 396.7 | 405.0 | 486.4 | 307.6 | 39.3 | 42.3 | 6.0 | 0.1 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Retained Earnings | -822.2 | -837.3 | -798.7 | -759.3 | -737.5 | -704.7 | -658.0 | -614.1 | -571.9 | -534.6 | |
| Comprehensive Income | 0.0 | 0.0 | 0.2 | 0.3 | 0.8 | -0.4 | -0.6 | -0.8 | -2.4 | -3.6 | |
| Total Common Equity | -29.4 | -44.7 | 34.0 | 70.9 | 84.4 | 9.9 | 47.8 | 88.1 | 120.4 | 148.5 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 378.9 | 369.5 | 17.8 | 19.5 | 21.0 | 0.3 | 2.2 | 8.3 | 14.4 | 13.8 | 4.9 | 4.9 | 0.9 | |
| Book Value | 9.9 | 70.9 | 88.1 | 262.1 | 356.4 | 396.7 | 405.0 | 486.4 | 307.6 | 39.3 | 42.3 | 6.0 | 0.1 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | -29.4 | -44.7 | 34.0 | 70.9 | 84.4 | 9.9 | 47.8 | 88.1 | 120.4 | 148.5 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -170.1 | 49.6 | -145.2 | -163.6 | -128.7 | -57.8 | -19.9 | -97.3 | -61.7 | -30.1 | -4.3 | -5.4 | 3.5 | -5.5 | |
| Depreciation & Amortization | 2.4 | 2.4 | 2.4 | 2.4 | 2.3 | 2.1 | 0.6 | 0.5 | 0.3 | 0.2 | 0.2 | 0.3 | 0.3 | 0.6 | |
| Stock-Based Compensation | 33.6 | 36.1 | 34.0 | 33.2 | 27.4 | 15.3 | 11.5 | 12.4 | 10.0 | 4.4 | 1.2 | 0.6 | 0.2 | 0.2 | |
| Change Working Capital | -10.3 | -80.7 | -66.3 | -0.3 | 6.8 | -7.5 | -6.8 | 16.9 | 3.5 | 4.1 | -7.0 | -6.5 | 9.3 | -1.2 | |
| Change In Accounts Receivable | -5.8 | 6.9 | -33.9 | 0.0 | -0.5 | -0.9 | 0.0 | 0.0 | 0.0 | 1.2 | 0.0 | 0.2 | -1.5 | 0.3 | |
| Change In Accounts Payable | -1.4 | -87.3 | -33.8 | 10.9 | 9.7 | -4.7 | -8.9 | 14.5 | 7.1 | 2.2 | 1.3 | 1.9 | 0.5 | -0.3 | |
| Change In Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -238.0 | -5.3 | 0.3 | -0.5 | 0.1 | |
| Other Non-cash Items | 40.6 | 12.3 | 39.8 | 7.6 | 18.6 | 1.5 | 0.5 | 0.7 | 0.6 | 0.6 | 0.1 | 0.1 | 1.3 | 0.9 | |
| Cash from Operations | -129.4 | 0.0 | 0.0 | -120.8 | -73.6 | -45.9 | -14.2 | -69.5 | -48.5 | -19.4 | -9.0 | -9.7 | 14.6 | -5.8 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 49.6 | 15.1 | -38.6 | -39.3 | -21.8 | -32.9 | -46.7 | -43.9 | -42.2 | -37.3 | |
| Depreciation & Amortization | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | |
| Stock-Based Compensation | 8.5 | 9.2 | 9.2 | 9.2 | 8.2 | 8.2 | 7.5 | 10.1 | 8.1 | 7.8 | |
| Change Working Capital | 19.9 | -73.6 | -29.5 | 2.5 | -68.8 | -1.3 | 8.7 | -7.4 | -2.7 | -9.0 | |
| Change In Accounts Receivable | 41.8 | -54.3 | -3.5 | 22.9 | -28.6 | 2.2 | -1.9 | -0.2 | -3.6 | -0.1 | |
| Change In Accounts Payable | -22.4 | -18.6 | -22.3 | -24.0 | -40.0 | 3.4 | 8.0 | -5.2 | -1.5 | -2.7 | |
| Change In Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Non-cash Items | 19.4 | 21.4 | 18.0 | 16.4 | 15.1 | 15.3 | 8.5 | 3.3 | 5.0 | 4.4 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -34.3 | -36.5 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.5 | -0.1 | -0.4 | -0.8 | -0.4 | -1.4 | -0.6 | -0.8 | -1.1 | -0.3 | -0.1 | -0.2 | -0.1 | 0.0 | |
| Acquisitions | -80.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 194.9 | 251.8 | 347.5 | 290.9 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | -344.5 | -196.4 | -380.4 | -303.9 | -802.5 | -118.7 | -194.9 | -251.8 | -347.5 | -290.9 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 491.0 | 424.5 | 476.1 | 449.5 | 408.0 | 158.8 | 290.0 | 384.1 | 206.1 | 48.1 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | 146.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -194.9 | -251.8 | -347.5 | -290.9 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Cash from Investing | 146.0 | 0.0 | 0.0 | 144.8 | -394.8 | 38.8 | 94.5 | 131.4 | -142.5 | -243.1 | -0.1 | -0.2 | -0.1 | 0.0 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | 0.0 | 0.0 | 0.0 | 0.0 | -0.3 | 0.0 | 0.0 | 0.0 | -0.3 | -0.2 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -49.5 | -30.8 | |
| Investments | 0.0 | -19.7 | -54.2 | -122.5 | -120.9 | -51.3 | -149.2 | -59.0 | -66.3 | -70.0 | |
| Sales of Investment | 73.5 | 123.0 | 90.7 | 137.4 | 91.7 | 110.0 | 146.7 | 127.6 | 115.8 | 100.8 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 49.5 | 30.8 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 49.2 | 30.6 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -41.8 | 0.0 | 0.0 | -11.7 | 0.0 | 0.0 | -1.4 | -7.5 | -6.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 402.1 | 369.5 | 351.6 | 10.1 | -1.5 | 20.6 | -0.5 | 1.5 | 0.7 | 0.6 | 8.9 | 0.0 | 4.0 | 0.9 | |
| Issuance of Common Stock | 2.2 | 0.0 | 0.0 | 2.5 | 11.8 | 2.6 | 0.0 | 0.0 | 227.5 | 292.5 | 0.0 | 0.2 | 0.0 | 0.0 | |
| Repurchase of Common Stock | 0.0 | -68.6 | -0.5 | -50.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 27.2 | 0.0 | 0.0 | 0.0 | 32.2 | 249.7 | 0.5 | 3.0 | 2.8 | -0.1 | 8.6 | 39.2 | 4.9 | 2.0 | |
| Cash from Financing | 20.0 | 0.0 | 0.0 | -59.3 | 44.0 | 252.3 | -0.9 | -4.5 | 223.4 | 292.5 | 8.6 | 39.4 | 4.9 | 2.0 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 346.5 | 331.4 | -0.5 | -0.5 | -0.5 | -0.5 | -310.6 | 309.8 | -0.4 | -0.4 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.2 | |
| Repurchase of Common Stock | -3.4 | -9.7 | -51.1 | -4.4 | -0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -5.4 | -3.2 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -5.2 | -3.1 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 36.6 | 115.1 | 87.1 | -35.3 | -424.4 | 245.2 | 79.4 | 57.4 | 32.4 | 30.0 | -0.5 | 29.5 | 19.4 | -3.9 | |
| Closing Cash Balance | 71.8 | 238.2 | 123.1 | 36.0 | 71.3 | 495.7 | 250.5 | 171.1 | 113.7 | 81.2 | 51.2 | 51.7 | 22.2 | 2.8 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 128.4 | 65.5 | -54.3 | -24.4 | -68.5 | 119.8 | 18.1 | 17.7 | 9.7 | -8.9 | |
| Closing Cash Balance | 238.2 | 109.8 | 44.3 | 98.6 | 123.1 | 191.6 | 71.8 | 53.7 | 36.0 | 26.3 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -129.9 | 19.6 | -135.7 | -121.6 | -74.0 | -47.3 | -14.7 | -70.3 | -49.6 | -19.7 | -9.1 | -9.9 | 14.5 | -5.8 | |
| Real Free Cash Flow | -163.5 | -16.5 | -169.7 | -154.8 | -101.3 | -62.6 | -26.2 | -82.7 | -59.5 | -24.1 | -10.2 | -10.5 | 14.3 | -6.0 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 98.0 | -27.4 | -40.3 | -10.7 | -66.9 | -10.1 | -21.4 | -37.3 | -34.6 | -36.6 | |
| Real Free Cash Flow | 89.5 | -36.5 | -49.5 | -19.9 | -75.1 | -18.3 | -28.9 | -47.4 | -42.7 | -44.4 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | -147.7 | -19.6 | -1.4 |
| P/S | 8.3 | 94.9 | 9.4 |
| P/B | -66.5 | 5.4 | 5.2 |
| P/FCF | -118.8 | 2.3 | -1.5 |
| Market cap | $0.9 | $0.8 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 98.1 % | 13.2 % | 0 % |
| Debt to Income | -2618.3 % | -57.7 % | 0 % |
| Debt to Free cash flow | -2104.5 % | -1605.9 % | 0 % |
| Interest expense percentage | 166.8 % | -14.5 % | 44.7 % |
| Current ratio | 8.7 | 13.5 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 45 % | -67.6 % | 0 % |
| ROA | -3.7 % | -15.5 % | 0 % |
| CapEx to Revenue | 0.2 % | 4.2 % | 0 % |
| RaD to Revenue | 0 % | 468.3 % | 0 % |
| ROEM | 1,725,022.1 | 214918.9 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 9.7 % | 96.8 % | 68.7 % |
| Operating margin | -16.9 % | -504.5 % | 35.5 % |
| Net margin | -49.9 % | -521.1 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | -0.1 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 29.0 mil | 35.3 mil |
| Employee count | 0.1 tis | 0.1 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
